Redeye provides its initial take on BONESUPPORT’s Q4 report and expects a positive reaction of c.5% in the stock. We are encouraged by the demonstrated continuous sales growth of 15% (21% in constant exchange rates) in a quarter where elective surgeries were severely halted towards the end.
LÄS MER
